Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).

Autor: Kijak, Gustavo H.1 (AUTHOR) gustavo.kijak@astrazeneca.com, Ahani, Bahar2 (AUTHOR), Arbetter, Douglas3 (AUTHOR), Chuecos, Fernando4 (AUTHOR), Gopalakrishnan, Vancheswaran2 (AUTHOR), Beloor, Jagadish1 (AUTHOR), Brady, Tyler1 (AUTHOR), Nguyen, Amy1 (AUTHOR), Roe, Tiffany L.1 (AUTHOR), Schuko, Nicolette1 (AUTHOR), Zhang, Tianhui5 (AUTHOR), Hobbs, F. D. Richard6 (AUTHOR), Padilla, Francisco7 (AUTHOR), Kelly, Elizabeth J.8 (AUTHOR), Montgomery, Hugh9 (AUTHOR), Streicher, Katie1 (AUTHOR)
Zdroj: Infectious Diseases & Therapy. Dec2023, Vol. 12 Issue 12, p2691-2707. 17p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje